|
Indications and Dosage
Ophthalmic
Non-infectious allergic conjunctivitis Adult: As 0.1% solution: Instil 1-2 drops into affected eye(s) 4 times daily.
Child: As 0.1% solution: ≥4 years Same as adult dose. Treatment recommendations may vary among countries (refer to specific country guidelines). |
|
Special Precautions
Children. Pregnancy and lactation.
|
|
Adverse Reactions
Significant: Eye discomfort, transient stinging or burning; blurred vision or visual disturbances.
Ear and labyrinth disorders: Eye pruritus, pain, oedema, discharge or irritation; increased lacrimation, ocular hyperaemia, asthenopia, corneal deposits, conjunctival oedema, abnormal sensation in eye, foreign body sensation in eyes, eyelid exfoliation. Gastrointestinal disorders: Nausea. General disorders and administration site conditions: Feeling hot or temporary warm sensation. Nervous system disorders: Headache, dizziness. Skin and subcutaneous tissue disorders: Skin rash. |
|
Ophth: B
|
|
Patient Counseling Information
This drug may cause temporary blurred vision or other visual disturbances, if affected, do not drive or operate machinery. Remove contact lenses prior to administration and reinsert after at least 15 minutes.
|
|
Monitoring Parameters
Monitor for eye discomfort, transient stinging or burning.
|
|
Action
Description:
Mechanism of Action: Lodoxamide is a mast cell stabiliser that blocks type 1, IgE-mediated (immediate) hypersensitivity reactions. It also inhibits the release and activation of mast cell inflammatory mediators such as histamine and leukotrienes (e.g. slow reacting substance of anaphylaxis) and prevents eosinophil chemotaxis. Pharmacokinetics: Excretion: Via urine. Elimination half-life: 8.5 hours. |
|
Chemical Structure
 Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 44564, Lodoxamide. https://pubchem.ncbi.nlm.nih.gov/compound/Lodoxamide. Accessed Apr. 28, 2024. |
|
Storage
Store between 20-25°C. Do not freeze.
|
|
ATC Classification
S01GX05 - lodoxamide ; Belongs to the class of other ophthalmologic antiallergics.
|
|
References
Alomide 0.1% w/v Eye Drops, Solution (Novartis Pharmaceuticals UK Limited). MHRA. https://products.mhra.gov.uk. Accessed 02/04/2024. Alomide Solution/Drops (Novartis Pharmaceuticals Corporation). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 02/04/2024. Anon. Lodoxamide. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 02/04/2024. Buckingham R (ed). Lodoxamide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/04/2024. Joint Formulary Committee. Lodoxamide. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 02/04/2024. Lodoxamide. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 02/04/2024. Novartis New Zealand Limited. Lodoxamide Trometamol 0.1% Eye Drops data sheet 25 May 2023. Medsafe. http://www.medsafe.govt.nz. Accessed 02/04/2024. Paediatric Formulary Committee. Lodoxamide. BNF for Children [online]. London. BMJ Group, Pharmaceutical Press, and RCPCH Publications. https://www.medicinescomplete.com. Accessed 02/04/2024.
|
Sign up for Free to Continue Reading
Continue with Google
Sign up with email
Already a member?
Sign in
Sign Out
